Related references
Note: Only part of the references are listed.Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
R. J. Motzer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Immunological effects of everolimus in patients with metastatic renal cell cancer
Charlotte M. Huijts et al.
INTERNATIONAL JOURNAL OF IMMUNOPATHOLOGY AND PHARMACOLOGY (2017)
Transcriptional profiling reveals functional dichotomy between human slan+ non-classical monocytes and myeloid dendritic cells
Nathalie van Leeuwen-Kerkhoff et al.
JOURNAL OF LEUKOCYTE BIOLOGY (2017)
New treatment options for metastatic renal cell carcinoma
Alejo Rodriguez-Vida et al.
ESMO OPEN (2017)
IMA901, a multipeptide cancer vaccine, plus sunitinib versus sunitinib alone, as first-line therapy for advanced or metastatic renal cell carcinoma (IMPRINT): a multicentre, open-label, randomised, controlled, phase 3 trial
Brian I. Rini et al.
LANCET ONCOLOGY (2016)
Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of melanoma patients
Alena Gros et al.
NATURE MEDICINE (2016)
Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade
Nicholas McGranahan et al.
SCIENCE (2016)
Neoantigens in cancer immunotherapy
Ton N. Schumacher et al.
SCIENCE (2015)
Sunitinib depletes myeloid-derived suppressor cells and synergizes with a cancer vaccine to enhance antigen-specific immune responses and tumor eradication
Oana Draghiciu et al.
ONCOIMMUNOLOGY (2015)
Immune Consequences of Decreasing Tumor Vasculature with Antiangiogenic Tyrosine Kinase Inhibitors in Combination with Therapeutic Vaccines
Benedetto Farsaci et al.
CANCER IMMUNOLOGY RESEARCH (2014)
Myeloid derived suppressor and dendritic cell subsets are related to clinical outcome in prostate cancer patients treated with prostate GVAX and ipilimumab
Saskia J. A. M. Santegoetst et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2014)
Persistent antigen at vaccination sites induces tumor-specific CD8+ T cell sequestration, dysfunction and deletion
Yared Hailemichael et al.
NATURE MEDICINE (2013)
The Vaccine-site Microenvironment Induced by Injection of Incomplete Freund's Adjuvant, With or Without Melanoma Peptides
Rebecca C. Harris et al.
JOURNAL OF IMMUNOTHERAPY (2012)
Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival
Steffen Walter et al.
NATURE MEDICINE (2012)
Whole Cell Vaccines-Past Progress and Future Strategies
Bridget P. Keenan et al.
SEMINARS IN ONCOLOGY (2012)
CpG Still Rocks! Update on an Accidental Drug
Arthur M. Krieg
NUCLEIC ACID THERAPEUTICS (2012)
Efficient In vivo Priming by Vaccination with Recombinant NY-ESO-1 Protein and CpG in Antigen Naive Prostate Cancer Patients
Julia Karbach et al.
CLINICAL CANCER RESEARCH (2011)
Intradermal Vaccinations With RNA Coding for TAA Generate CD8+ and CD4+ Immune Responses and Induce Clinical Benefit in Vaccinated Patients
Susanne M. Rittig et al.
MOLECULAR THERAPY (2011)
Ten-year survival analysis for renal carcinoma patients treated with an autologous tumour lysate vaccine in an adjuvant setting
Matthias May et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2010)
Direct and Differential Suppression of Myeloid-Derived Suppressor Cell Subsets by Sunitinib Is Compartmentally Constrained
Jennifer S. Ko et al.
CANCER RESEARCH (2010)
Tumor-reactive CD8+ T-cell responses after vaccination with NY-ESO-1 peptide, CpG 7909 and Montanide® ISA-51: association with survival
Julia Karbach et al.
INTERNATIONAL JOURNAL OF CANCER (2010)
Memory and Effector CD8 T-cell Responses After Nanoparticle Vaccination of Melanoma Patients
Daniel E. Speiser et al.
JOURNAL OF IMMUNOTHERAPY (2010)
Phase 1 Trial of the Plasmodium falciparum Blood Stage Vaccine MSP142-C1/Alhydrogel with and without CPG 7909 in Malaria Naive Adults
Ruth D. Ellis et al.
PLOS ONE (2010)
Sunitinib Mediates Reversal of Myeloid-Derived Suppressor Cell Accumulation in Renal Cell Carcinoma Patients
Jennifer S. Ko et al.
CLINICAL CANCER RESEARCH (2009)
Sunitinib-induced myeloid lineage redistribution in renal cell cancer patients:: CD1c+ dendritic cell frequency predicts progression-free survival
Hester van Cruijsen et al.
CLINICAL CANCER RESEARCH (2008)
Local administration of PF-3512676 CpG-B instigates tumor-specific CD8+ T-cell reactivity in melanoma patients
Barbara G. Molenkamp et al.
CLINICAL CANCER RESEARCH (2008)
Sunitinib Reverses Type-1 Immune Suppression and Decreases T-Regulatory Cells in Renal Cell Carcinoma Patients
James H. Finke et al.
CLINICAL CANCER RESEARCH (2008)
Toll-like receptor 9 (TLR9) agonists in the treatment of cancer
A. M. Krieg
ONCOGENE (2008)
Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte-macrophage colony-stimulation factor based antitumor vaccine
Paola Filipazzi et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Activation-induced FOXP3 in human T effector cells does not suppress proliferation or cytokine production
Sarah E. Allan et al.
INTERNATIONAL IMMUNOLOGY (2007)
Transient expression of FOXP3 in human activated nonregulatory CD4(+) T cells
Jun Wang et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2007)
Single-cell analysis of normal and FOXP3-mutant human T cells: FOXP3 expression without regulatory T cell development (vol 103, pg 6659, 2006)
MA Gavin et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Immunologic and clinical responses after vaccinations with peptide-pulsed dendritic cells in metastatic renal cancer patients
Jan Wierecky et al.
CANCER RESEARCH (2006)
Single-cell analysis of normal and FOXP3-mutant human T cells: FOXP3 expression without regulatory T cell development
MA Gavin et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal-cell carcinoma after radical nephrectomy: phase III, randomised controlled trial
D Jocham et al.
LANCET (2004)
Immunopharmacologic analysis of an autologous, hapten-modified human melanoma vaccine
D Berd et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
A phase I study of the safety and immunogenicity of recombinant hepatitis B surface antigen co-administered with an immunostimulatory phosphorothioate oligonucleotide adjuvant
SA Halperin et al.
VACCINE (2003)
6-sulfo LacNAc, a novel carbohydrate modification of PSGL-1, defines an inflammatory type of human dendritic cells
K Schäkel et al.
IMMUNITY (2002)
A phase II study of active specific immunotherapy and 5-FU/Leucovorin as adjuvant therapy for stage III colon carcinoma
A Baars et al.
BRITISH JOURNAL OF CANCER (2002)
BDCA-2, a novel plasmacytoid dendritic cell-specific type IIC-type lectin, mediates antigen capture and is a potent inhibitor of interferon α/β induction
A Dzionek et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2001)
Skin tests predict survival after autologous tumor cell vaccination in metastatic melanoma: Experience in 81 patients
A Baars et al.
ANNALS OF ONCOLOGY (2000)
Share Paper
